Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
| dc.contributor.author | Jones, S. | |
| dc.contributor.author | Statsenko, G. | |
| dc.contributor.author | Voitko, O. | |
| dc.contributor.author | Conev, N. V. | |
| dc.contributor.author | Bondarenko, I. | |
| dc.contributor.author | Spencer, S. | |
| dc.contributor.author | Xie, M. | |
| dc.contributor.author | Franks, A. | |
| dc.contributor.author | Paz-Ares, L. | |
| dc.contributor.author | Shrestha, Y. | |
| dc.contributor.author | Goldman, J. W. | |
| dc.contributor.author | Garassino, M. C. | |
| dc.contributor.author | Chen, Y. | |
| dc.contributor.author | Reinmuth, N. | |
| dc.contributor.author | Hotta, K. | |
| dc.contributor.author | Poltoratskiy, A. | |
| dc.contributor.author | Trukhin, D. | |
| dc.contributor.author | Hochmair, M. J. | |
| dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
| dc.contributor.author | Ji, J. H. | |
| dc.date.accessioned | 2021-03-02T17:08:04Z | |
| dc.date.available | 2021-03-02T17:08:04Z | |
| dc.identifier.citation | Goldman J. W. , Garassino M. C. , Chen Y., Reinmuth N., Hotta K., Poltoratskiy A., Trukhin D., Hochmair M. J. , ÖZGÜROĞLU M., Ji J. H. , et al., "Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN", ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 | |
| dc.identifier.other | av_4fe7d812-f085-4e15-bf8e-72061bf39ba0 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/3632 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2020.08.2328 | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | ONKOLOJİ | |
| dc.title | Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN | |
| dc.type | Bildiri | |
| dc.contributor.department | David Geffen School of Medicine at UCLA , , | |
| dc.identifier.volume | 31 | |
| dc.contributor.firstauthorID | 2286871 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]